Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis

Bintou Ahmadou Ahidjo,William R Bishai

doi:10.1016/j.ebiom.2016.02.016

Bintou Ahmadou Ahidjo, William R Bishai

Open Access

https://doi.org/10.1016/j.ebiom.2016.02.016

Copy DOI

Abstract

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis

Highlights

Mycobacterium tuberculosis (Mtb) interferes with immune signaling by secreting another bacterial-derived second messenger, cyclic-di-adenosine monophosphate (c-di-AMP) (Dey et al, 2015)
Success in modulating immunity may lead to treatment shortening by reducing granulomatous pathology and the bacterial persister-state associated with granulomas
PDE4 inhibitors have been of particular interest for lung infections since they reduce pulmonary inflammation

Summary

Introduction

Mtb interferes with immune signaling by secreting another bacterial-derived second messenger, cyclic-di-adenosine monophosphate (c-di-AMP) (Dey et al, 2015). Adjunctive hostdirected therapies (HDTs) for TB are currently being explored to improve treatment outcomes by restoring effective host immunity, achieving an appropriate degree of inflammation, and preventing disease-associated lung pathology (Wallis and Hafner, 2015). Success in modulating immunity may lead to treatment shortening by reducing granulomatous pathology and the bacterial persister-state associated with granulomas.

Results

Conclusion